Vif Substitution Enables Persistent Infection of Pig-Tailed Macaques by Human Immunodeficiency Virus Type 1

被引:32
|
作者
Thippeshappa, Rajesh [1 ]
Polacino, Patricia [5 ]
Kimata, Monica T. Yu [1 ]
Siwak, Edward B. [1 ]
Anderson, David [5 ]
Wang, Weiming [3 ]
Sherwood, Laura [2 ]
Arora, Reetakshi [1 ]
Wen, Michael [3 ]
Zhou, Paul [3 ]
Hu, Shiu-Lok [4 ,5 ]
Kimata, Jason T. [1 ]
机构
[1] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA
[2] SW Fdn Biomed Res, Dept Virol & Immunol, San Antonio, TX 78227 USA
[3] Chinese Acad Sci, Inst Pasteur Shanghai, Antiviral Immun & Gene Therapy Unit, Shanghai 200025, Peoples R China
[4] Univ Washington, Dept Pharmaceut, Seattle, WA 98121 USA
[5] Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98121 USA
关键词
HIV-1 REVERSE TRANSCRIPTION; BLOOD MONONUCLEAR-CELLS; FUSION INHIBITOR T-20; CD4(+) T-CELLS; MACACA-NEMESTRINA; CYTIDINE DEAMINASE; ACCESSORY PROTEINS; HUMAN APOBEC3G; NEUTRALIZING ANTIBODY; PIGTAILED MACAQUES;
D O I
10.1128/JVI.02438-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Among Old World monkeys, pig-tailed macaques (Pt) are uniquely susceptible to human immunodeficiency virus type 1 (HIV-1), although the infection does not persist. We demonstrate that the susceptibility of Pt T cells to HIV-1 infection is due to the absence of postentry inhibition by a TRIM5 isoform. Notably, substitution of the viral infectivity factor protein, Vif, with that from pathogenic SIVmne enabled replication of HIV-1 in Pt T cells in vitro. When inoculated into juvenile pig-tailed macaques, the Pt-tropic HIV-1 persistently replicated for more than 1.5 to 2 years, producing low but measurable plasma viral loads and persistent proviral DNA in peripheral blood mononuclear cells. It also elicited strong antibody responses. However, there was no decline in CD4(+) T cells or evidence of disease. Surprisingly, the Pt-tropic HIV-1 was rapidly controlled when inoculated into newborn Pt macaques, although it transiently rebounded after 6 months. We identified two notable differences between the Pt-tropic HIV-1 and SIVmne. First, SIV Vif does not associate with Pt-tropic HIV-1 viral particles. Second, while Pt-tropic HIV-1 degrades both Pt APOBEC3G and APOBEC3F, it prevents their inclusion in virions to a lesser extent than pathogenic SIVmne. Thus, while SIV Vif is necessary for persistent infection by Pt-tropic HIV-1, improved expression and inhibition of APOBEC3 proteins may be required for robust viral replication in vivo. Additional adaptation of the virus may also be necessary to enhance viral replication. Nevertheless, our data suggest the potential for the pig-tailed macaque to be developed as an animal model of HIV-1 infection and disease.
引用
收藏
页码:3767 / 3779
页数:13
相关论文
共 49 条
  • [41] Designed recombinant adenovirus type 5 vector induced envelope-specific CD8+ cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1
    Ura, Takehiro
    Yoshida, Atsushi
    Xin, Ke-Qin
    Yoshizaki, Shinji
    Yashima, Sayaka
    Abe, Shinya
    Mizuguchi, Hiroyuki
    Okuda, Kenji
    JOURNAL OF GENE MEDICINE, 2009, 11 (02): : 139 - 149
  • [42] Systematic Interaction Analysis of Anti-Human Immunodeficiency Virus Type-1 Neutralizing Antibodies with High Mannose Glycans Using Fragment Molecular Orbital and Molecular Dynamics Methods
    Kusumoto, Miyu
    Ueno-Noto, Kaori
    Takano, Keiko
    JOURNAL OF COMPUTATIONAL CHEMISTRY, 2020, 41 (01) : 31 - 42
  • [43] Cross-Neutralizing CRF01_AE-Infected Plasma from Malaysia Targets CD4-Binding Site of Human Immunodeficiency Virus Type-1 Envelope Glycoprotein
    Ng, Qi Ron
    Tee, Kok Keng
    Binley, James M.
    Tong, Tommy
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2022, 38 (02) : 162 - 172
  • [44] Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: Its deletion leads to a strong neutralizing response
    Cleveland, SM
    Buratti, E
    Jones, TD
    North, P
    Baralle, F
    McLain, L
    McInerney, T
    Durrani, Z
    Dimmock, NJ
    VIROLOGY, 2000, 266 (01) : 66 - 78
  • [45] Detection of Hepatitis B Virus (HBV) Genomes and HBV Drug Resistant Variants by Deep Sequencing Analysis of HBV Genomes in Immune Cell Subsets of HBV Mono-Infected and/or Human Immunodeficiency Virus Type-1 (HIV-1) and HBV Co-Infected Individuals
    Lee, Z.
    Nishikawa, S.
    Gao, S.
    Eksteen, J. B.
    Czub, M.
    Gill, M. J.
    Osiowy, C.
    van der Meer, F.
    van Marle, G.
    Coffin, C. S.
    PLOS ONE, 2015, 10 (09):
  • [46] Similar Immunological Profiles Between African Endemic and Human Immunodeficiency Virus Type 1-Associated Epidemic Kaposi Sarcoma (KS) Patients Reveal the Primary Role of KS-Associated Herpesvirus in KS Pathogenesis
    Lidenge, Salum J.
    Tso, For Yue
    Ngalamika, Owen
    Ngowi, John R.
    Mortazavi, Yasaman
    Kwon, Eun Hee
    Shea, Danielle M.
    Minhas, Veenu
    Mwaiselage, Julius
    Wood, Charles
    West, John T.
    JOURNAL OF INFECTIOUS DISEASES, 2019, 219 (08): : 1318 - 1328
  • [47] Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E
    Wang, Shixia
    Pal, Ranajit
    Mascola, John R.
    Chou, Te-Hui W.
    Mboudjeka, Innocent
    Shen, Siyuan
    Liu, Qin
    Whitney, Stephen
    Keen, Timothy
    Nair, B. C.
    Kalyanaraman, V. S.
    Markham, Philip
    Lu, Shan
    VIROLOGY, 2006, 350 (01) : 34 - 47
  • [48] Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site
    Utachee, Piraporn
    Isarangkura-na-Ayuthaya, Panasda
    Tokunaga, Kenzo
    Ikuta, Kazuyoshi
    Takeda, Naokazu
    Kameoka, Masanori
    RETROVIROLOGY, 2014, 11
  • [49] Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site
    Piraporn Utachee
    Panasda Isarangkura-na-ayuthaya
    Kenzo Tokunaga
    Kazuyoshi Ikuta
    Naokazu Takeda
    Masanori Kameoka
    Retrovirology, 11